Combining a deep understanding of the immune system with its strong and accurate molecular diagnostic capabilities, makes Lophius the ideal partner to develop truly novel diagnostic solutions. Lophius has gained significant expertise through developing a novel diagnostic test to personalize cytomegalovirus (CMV) infection management from inception all the way to a CE-marked IVD product.
Lophius is dedicated to advancing its key development program in tuberculosis (TB) while further increasing the uptake of its T-Track® CMV diagnostic kit and expanding its portfolio of disease-relevant biomarkers. With our goal of transforming treatment paradigms and patient management using novel molecular diagnostic solutions, we are always interested in new collaborations with innovative, science-driven organizations, academic institutions and commercial partners. Lophius was able to attract a number of research alliances and is continuously building its distribution partner network to increase the market share of its T-Track® CMV diagnostic solution.
Lophius' technologies enable the pathogen-specific stimulation of a broad spectrum of clinically-relevant effector cells and the identification of markers secreted by these cells facilitating the development of novel molecular diagnostic solutions.
Our core program addresses an unmet clinical need in tuberculosis (TB), an often underestimated global epidemic. TB remains one of the 10 leading causes of death worldwide with around 1.5 million casualties each year.
We have successfully developedand and are already commercializing our clinically-validated CE marked diagnostic kit T-Track® CMV to individualize transplant patient management by allowing personalized cytomegalovirus (CMV) disease risk stratification.